ArticleTargeted oncology2026
Evaluation of Olaparib Efficacy Following CDK4/6 Inhibitor Therapy in BRCA-Mutated, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Turkish Oncology Group (TOG) Study.
Article in Targeted oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
55 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPoly(ADP-ribose) polymerase (PARP) inhibitors are established treatment options for patients with germline BRCA1/2-mutated hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer. However, evidence regarding their optimal sequencing after cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor-based therapy remains limited.
objectiveTo evaluate the real-world efficacy and safety of olaparib after prior CDK4/6 inhibitor plus endocrine therapy, with particular emphasis on treatment sequence and line of olaparib use. PATIENTS AND
methodsThis multicenter real-world retrospective study included patients with HR+/HER2- metastatic breast cancer harboring germline BRCA1/2 pathogenic variants who received olaparib after prior CDK4/6 inhibitor plus endocrine therapy. We retrospectively collected clinical characteristics, treatment sequence, response, survival outcomes, and olaparib-related adverse events. We evaluated progression-free survival (PFS), objective response rate (ORR), and treatment-related adverse events.
resultsWe included 52 patients from 28 institutions. Median age at olaparib initiation was 49.9 years [interquartile range (IQR), 40.2-59.0 years], and median follow-up was 12.84 months (95% confidence interval [CI], 10.52-15.15). The ORR was 57.7%. Median PFS was 11.0 months (95% CI 5.94-16.05), and the 12-month overall survival rate was 78.7%. Immediate post-CDK4/6 inhibitor olaparib use was associated with a numerically longer median PFS than use after intervening systemic treatment, although the difference was not statistically significant (13.4 versus 8.4 months; p = 0.088). Earlier-line olaparib use (≤ third line) was associated with longer PFS than later-line use (≥ fourth line) (17.7 versus 8.4 months; p = 0.005). No unexpected safety signals were observed.
conclusionsOlaparib demonstrated clinically meaningful activity and manageable safety after prior CDK4/6 inhibitor therapy in patients with germline BRCA1/2-mutated HR+/HER2- metastatic breast cancer. Earlier-line olaparib use was associated with longer PFS, although this nonrandomized finding should be interpreted cautiously and requires prospective validation.
Identifiers
42907609What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.